The cardioprotective effects of levosimendan: Preclinical and clinical evidence

Journal of Cardiovascular Pharmacology

Volumn 50, Issue 3, 2007, Pages 257-263

  Pollesello, Piero ^a   Papp, Zoltán ^b  

^a ORION CORPORATION   (Finland)

^b UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Apoptosis; ATP dependent potassium channels; Cardioprotection; Levosimendan; Preconditioning; Preoperative settings

Indexed keywords

ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; DIAZOXIDE; DOBUTAMINE; LEVOSIMENDAN; MILRINONE; PIMOBENDAN; PINACIDIL; PLACEBO; TROPONIN I;

ACUTE HEART FAILURE; ADULT RESPIRATORY DISTRESS SYNDROME; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; DISEASE ASSOCIATION; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; GUINEA PIG; HEART ARRHYTHMIA; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; HYPERTENSION; ISCHEMIC PRECONDITIONING; ISOLATED HEART; KIDNEY FAILURE; MITOCHONDRION; NONHUMAN; POTASSIUM TRANSPORT; PRIORITY JOURNAL; RABBIT; REPERFUSION INJURY; REVIEW; SEPTIC SHOCK;

ANIMALS; CARDIOTONIC AGENTS; DRUG EVALUATION, PRECLINICAL; HUMANS; HYDRAZONES; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MITOCHONDRIA, HEART; MYOCARDIAL REPERFUSION INJURY; POTASSIUM CHANNELS; PYRIDAZINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 34548725115     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3180986230     Document Type: Review

References (58)

1. Haikala H, Kaivola J, Nissinen E, et al. Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan. J Mol Cell Cardiol. 1995;27:1859-1866.
2. Jamali IN, Kersten JR, Pagel PS, et al. Intracoronary levosimendan enhances contractile function of stunned myocardium. Anesth Analg. 1997;85:23-29.
3. De Witt BJ, Ibrahim IN, Bayer E, et al. An analysis of responses to levosimendan in the pulmonary vascular bed of the cat. Anesth Analg. 2002;94:1427-1433.
4. Du Toit EF, Muller CA, McCarthy J, et al. Levosimendan: effects of a calcium sensitizer on function and arrhythmias and cyclic nucleotide levels during ischemia/reperfusion in the Langendorff-perfused guinea pig heart. J Pharmacol Exp Ther. 1999;290:505-514.
5. Yokoshiki H, Katsube Y, Sunagawa M, et al. Levosimendan, a novel Ca2+ sensitizer, activates the glibenclamide-sensitive K+ channel in rat arterial myocytes. Eur J Pharmacol. 1997;333:249-259.
6. Pataricza J, Hohn J, Petri A, et al. Comparison of the vasorelaxing effect of cromakalim and the new inodilator, levosimendan, in human isolated portal vein. J Pharm Pharmacol. 2000;52:213-217.
7. Kaheinen P, Pollesello P, Levijoki J, et al. Levosimendan increases diastolic coronary flow in isolated guinea-pig heart by opening ATP-sensitive potassium channels. J Cardiovasc Pharmacol. 2001;37:367-374.
8. Szilagyi S, Pollesello P, Levijoki J, et al. The effects of levosimendan and OR-1896 on isolated hearts, myocyte-sized preparations and phosphodiesterase enzymes of the guinea pig. Eur J Pharmacol. 2004;486:67-74.
9. Erdei N, Papp Z, Pollesello P, et al. The levosimendan metabolite OR-1896 elicits vasodilation by activating the K(ATP) and BK(Ca) channels in rat isolated arterioles. Br J Pharmacol. 2006;148:696-702.
10. Eriksson O, Pollesello P, Haikala H. Effect of levosimendan on balance between ATP production and consumption in isolated perfused guinea-pig heart before ischemia or after reperfusion. J Cardiovasc Pharmacol. 2004;44:316-321.
11. Kaheinen P, Pollesello P, Levijoki J, et al. Effects of levosimendan and milrinone on oxygen consumption in isolated guinea-pig heart. J Cardiovasc Pharmacol. 2004;43:555-561.
12. De Luca L, Colucci WS, Nieminen MS, et al. Evidence-based use of levosimendan in different clinical settings. Eur Heart J. 2006;27:1908-1920.
13. De Luca L, Sardella G, Proietti P, et al. Effects of levosimendan on left ventricular diastolic function after primary angioplasty for acute anterior myocardial infarction: a Doppler echocardiographic study. J Am Soc Echocardiogr. 2006;19:172-177.
14. Grover GJ, Garlid KD. ATP-Sensitive potassium channels: a review of their cardioprotective pharmacology. J Mol Cell Cardiol. 2000;32:677-695.
15. Gross GJ. The role of mitochondrial KATP channels in cardioprotection. Basic Res Cardiol. 2000;95:280-284.
16. Terzic A, Dzeja PP, Holmuhamedov EL. Mitochondrial K(ATP) channels: probing molecular identity and pharmacology. J Mol Cell Cardiol. 2000;32:1911-1915.
17. Szewczyk A, Marban E. Mitochondria: a new target for K channel openers? Trends Pharmacol Sci. 1999;20:157-161.
18. Inoue I, Nagase H, Kishi K, et al. ATP-sensitive K+ channel in the mitochondrial inner membrane. Nature. 1991;352:244-247.
19. Kowaltowski AJ, Seetharaman S, Paucek P, et al. Bioenergetic consequences of opening the ATP-sensitive K(+) channel of heart mitochondria. Am J Physiol Heart Circ Physiol. 2001;280:H649-H657.
20. Garlid KD, Dos SP, Xie ZJ, et al. Mitochondrial potassium transport: the role of the mitochondrial ATP-sensitive K(+) channel in cardiac function and cardioprotection. Biochim Biophys Acta. 2003;1606:1-21.
21. Pollesello P, Mebazaa A. ATP-dependent potassium channels as a key target for the treatment of myocardial and vascular dysfunction. Curr Opin Crit Care. 2004;10:436-441.
22. IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet. 2002;359:1269-1275.
23. Joseph T, Coirault C, Ducros L, et al. Mechanical and energetic effects of cromakalim on guinea pig left ventricular papillary muscle. J Pharmacol Exp Ther. 1996;279:464-471.
24. Cleland JG, Nikitin N, McGowan J. Levosimendan: first in a new class of inodilator for acute and chronic severe heart failure. Expert Rev Cardiovasc Ther. 2004;2:9-19.
25. Kopustinskiene DM, Pollesello P, Saris NE. Levosimendan is a mitochondrial K(ATP) channel opener. Eur J Pharmacol. 2001;428:311-314.
26. Kopustinskiene DM, Pollesello P, Saris NE. Potassium-specific effects of levosimendan on heart mitochondria. Biochem Pharmacol. 2004;68:807-812.
27. Maytin M, Colucci WS. Cardioprotection: a new paradigm in the management of acute heart failure syndromes. Am J Cardiol. 2005;96:26G-31G.
28. Louhelainen M, Vahtola E, Kaheinen P, et al. Effects of levosimendan on cardiac remodeling and cardiomyocyte apoptosis in hypertensive Dahl/ Rapp rats. Br J Pharmacol. 2007;150:851-861.
29. Du Toit EF, Genis A, Pollesello P, et al. Levosimendan, a new antifailure inodilator, has cardioprotective properties mediated by mitochondrial K-ATP channels. J Mol Cell Cardiol. (Manuscript submitted).
30. Lepran I, Pollesello P, Vajda S, et al. Preconditioning effects of levosimendan in a rabbit cardiac ischemia-reperfusion model. J Cardiovasc Pharmacol. 2006;48:148-152.
31. Papp JG, Pollesello P, Varro AF, et al. Effect of levosimendan and milrinone on regional myocardial ischemia/reperfusion-induced arrhythmias in dogs. J Cardiovasc Pharmacol Ther. 2006;11:129-135.
32. Kersten JR, Montgomery MW, Pagel PS, et al. Levosimendan, a new positive inotropic drug, decreases myocardial infarct size via activation of K(ATP) channels. Anesth Analg. 2000;90:5-11.
33. Cammarata GA, Weil MH, Sun S, et al. Levosimendan improves cardiopulmonary resuscitation and survival by K(ATP) channel activation. J Am Coll Cardiol. 2006;47:1083-1085.
34. Metzsch C, Liao Q, Steen S, et al. Levosimendan cardioprotection reduces the metabolic response during temporary regional coronary occlusion in an open chest pig model. Acta Anaesthesiol Scand. 2007;51:86-93.
35. Morelli A, De Castro S, Teboul JL, et al. Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression. Intensive Care Med. 2005;31:638-644.
36. Morelli A, Teboul JL, Maggiore SM, et al. Effects of levosimendan on right ventricular afterload in patients with acute respiratory distress syndrome: a pilot study. Crit Care Med. 2006;34:2287-2293.
37. Garcia-Gonzalez MJ, Dominguez-Rodriguez A, Ferrer-Hita JJ, et al. Cardiogenic shock after primary percutaneous coronary intervention: Effects of levosimendan compared with dobutamine on haemodynamics. Eur J Heart Fail. 2006;8:723-728.
38. De Luca L, Proietti P, Celotto A, et al. Levosimendan improves hemodynamics and coronary flow reserve after percutaneous coronary intervention in patients with acute myocardial infarction and left ventricular dysfunction. Am Heart J. 2005;150:563-568.
39. Akgul A, Mavioglu L, Katircioglu SF, et al. Levosimendan for weaning from cardiopulmonary bypass after coronary artery bypass grafting. Heart Lung Circ. 2006;15:320-324.
40. Al Shawaf E, Ayed A, Vislocky I, et al. Levosimendan or milrinone in the type 2 diabetic patient with low ejection fraction undergoing elective coronary artery surgery. J Cardiothorac Vasc Anesth. 2006;20:353-357.
41. Morais RJ. Levosimendan in severe right ventricular failure following mitral valve replacement. J Cardiothorac Vasc Anesth. 2006;20:82-84.
42. Braun JP, Jasulaitis D, Moshirzadeh M, et al. Levosimendan may improve survival in patients requiring mechanical assist devices for postcardiotomy heart failure. Crit Care. 2006;10:R17.
43. Raja SG, Rayen BS. Levosimendan in cardiac surgery: current best available evidence. Ann Thorac Surg. 2006;81:1536-1546.
44. Toller WG, Metzler H. Acute perioperative heart failure. Curr Opin Anaesthesiol. 2005;18:129-135.
45. Tritapepe L, De Santis, V, Vitale D, et al. Preconditioning effects of levosimendan in coronary artery bypass grafting - a pilot study. Br J Anaesth. 2006;96:694-700.
46. Eriksson H, Jalonen J, Heikkinen L, et al. Levosimendan enhances weaning from cardiopulmonary bypass (CPB) in patients with compromised heart function after coronary artery bypass graft (CABG) surgery. In: Proceedings of the Society of Cardiothoracic Anaesthesiology, 29th Annual Meeting. Montreal, Canada: Society of Cardiothoracic Anaesthesiology; 2007:70-71.
47. Prior DL, Flaim BD, MacIsaac AI, et al. Pre-operative use of levosimendan in two patients with severe aortic stenosis and left ventricular dysfunction. Heart Lung Circ. 2006;15:56-58.
48. Pagel PS, Hettrick DA, Warltier DC. Influence of levosimendan, pimobendan, and milrinone on the regional distribution of cardiac output in anaesthetized dogs. Br J Pharmacol. 1996;119:609-615.
49. Schwarte LA, Picker O, Bornstein SR, et al. Levosimendan is superior to milrinone and dobutamine in selectively increasing microvascular gastric mucosal oxygenation in dogs. Crit Care Med. 2005;33:135-142.
50. Woolsey CA, Coopersmith CM. Vasoactive drugs and the gut: is there anything new? Curr Opin Crit Care. 2006;12:155-159.
51. Zager RA, Johnson AC, Lund S, et al. Levosimendan protects against experimental endotoxemic acute renal failure. Am J Physiol Renal Physiol. 2006;290:F1453-F1462.
52. Faivre V, Kaskos H, Callebert J, et al. Cardiac and renal effects of levosimendan, arginine vasopressin, and norepinephrine in lipopolysaccharide- treated rabbits. Anesthesiology. 2005;103:514-521.
53. Raftopoulos SC. Levosimendan following coronary artery bypass grafting in a patient with end-stage renal failure: a case report. Crit Care Resusc. 2004;6:109-112.
54. Cardoso JS, Ferreira J, Oliveira-Soares A, et al. Levosimendan in daily intensive care practice - the experience of 15 centers. The PORTLAND study. J Cardiac Fail. 2004;10(Suppl 4):131.
55. Follath F, Cleland JG, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet. 2002;360:196-202.
56. Moiseyev VS, Poder P, Andrejevs N, et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J. 2002;23:1422-1432.
57. Cleland JG, Ghosh J, Freemantle N, et al. Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure. Eur J Heart Fail. 2004;6:501-508.
58. Papp Z, Csapó K, Pollesello P, et al. Pharmacological mechanisms contributing to the clinical efficacy of levosimendan. Drug Rev. 2005;23:71-98.